Veracyte, Inc.
Veracyte operates as a diagnostics company offering tests for various cancers, including thyroid, prostate, breast, lung, and lymphoma. Products include Afirma, Decipher, Prosigna, Percepta, and Envisia. The company also develops the nCounter analysis system and LymphMark test.
Overview
Strengths
- Valued below its Diagnostics & Research peers: P/FCF 15.0x vs. a median of 24.7x.
- Consistent growth: revenue has compounded at 34.5% a year over 5 years, rising every year.
- Improving fundamentals over the last year: return on assets up 2.9 points, gross margin up 3.2 points and asset turnover up 7.3%.
- Cheaper than its own history: P/FCF 15.0x vs. a historical average of 68.0x and EV/EBITDA 14.0x vs. a historical average of 74.2x.
- Earnings are projected to grow at a solid rate (20.0% per year).
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 10.1%) has been below its cost of capital of 11.4% in each of the last 6 years.
- Unreliable cash generation: free cash flow was negative in 3 of the last 6 years.
- Unstable profitability: operating margin ranged from -37% to 15% over the last 6 years, with operating losses in 4 of them.
- Shareholder dilution: the share count has grown by 3.3% a year over the last three years.
Key Financial Data